William N Charman

发表

Lymphatic Transport of Methylnortestosterone Undecanoate (MU) and the Bioavailability of Methylnortestosterone Are Highly Sensitive to the Mass of Coadministered Lipid after Oral Administration of MU

Christopher J H Porter, Karen L White, G. Edwards, 2009, Journal of Pharmacology and Experimental Therapeutics.

Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target

Yongyuth Yuthavong, Sumalee Kamchonwongpaisan, Jarunee Vanichtanankul, 2012, Proceedings of the National Academy of Sciences.

Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria

Christian Scheurer, Lukas Stingelin, David M. Shackleford, 2011, Proceedings of the National Academy of Sciences.

Alteration of the intravenous pharmacokinetics of a synthetic ozonide antimalarial in the presence of a modified cyclodextrin.

Susan A Charman, R. Prankerd, S. Charman, 2006, Journal of pharmaceutical sciences.

Lipid-based delivery systems and intestinal lymphatic drug transport: A mechanistic update☆

Christopher J H Porter, Natalie L Trevaskis, C. Porter, 2007, Advanced Drug Delivery Reviews.

Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice.

David M. Shackleford, Susan A Charman, Pradipsinh K Rathod, 2011, Journal of medicinal chemistry.

50years of oral lipid-based formulations: Provenance, progress and future perspectives.

Christel A. S. Bergström, Hywel D Williams, Christopher J H Porter, 2016, Advanced drug delivery reviews.

Contribution of Lymphatically Transported Testosterone Undecanoate to the Systemic Exposure of Testosterone after Oral Administration of Two Andriol Formulations in Conscious Lymph Duct-Cannulated Dogs

David M. Shackleford, Christopher J H Porter, G. Edwards, 2003, Journal of Pharmacology and Experimental Therapeutics.

The Mucosa of the Small Intestine

W. Charman, William N Charman, Margaret M Doherty, 2002, Clinical pharmacokinetics.

The binding interaction of synthetic ozonide antimalarials with natural and modified beta-cyclodextrins.

Susan A Charman, Martin J Scanlon, R. Prankerd, 2006, Journal of pharmaceutical sciences.

Evaluation of the in‐vitro digestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products

Christopher J H Porter, Ann Marie Kaukonen, C. Porter, 2002, The Journal of pharmacy and pharmacology.

Synthesis, structure-activity relationships and brain uptake of a novel series of benzopyran inhibitors of insulin-regulated aminopeptidase.

Michael W Parker, Jessica K Holien, M. Parker, 2014, Journal of medicinal chemistry.

Probing drug solubilization patterns in the gastrointestinal tract after administration of lipid-based delivery systems: a phase diagram approach.

Ben J Boyd, Christopher J H Porter, B. Boyd, 2004, Journal of pharmaceutical sciences.

Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice.

David M. Shackleford, Pradipsinh K Rathod, Karen L White, 2009, Journal of medicinal chemistry.

Methods to assess drug permeability across the blood‐brain barrier

Susan A Charman, S. Charman, W. Charman, 2006, The Journal of pharmacy and pharmacology.

AN EXAMINATION OF THE INTERPLAY BETWEEN ENTEROCYTE-BASED METABOLISM AND LYMPHATIC DRUG TRANSPORT IN THE RAT

Christopher J H Porter, Natalie L Trevaskis, C. Porter, 2006, Drug Metabolism and Disposition.

Intravenous dosing conditions may affect systemic clearance for highly lipophilic drugs: implications for lymphatic transport and absolute bioavailability studies.

Christopher J H Porter, Natalie L Trevaskis, C. Porter, 2012, Journal of pharmaceutical sciences.